ReviewMedical oncology (Northwood, London, England)2025
Exosomal microRNAs as prostate cancer biomarkers and treatments: recent progress.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a significant global health concern and the second leading cause of death among males. It is known to affect nearby stromal cells. Exosomes assist these stromal cells in supporting cancer growth and spread. They also contribute to the initiation and dissemination of cancer, as well as to the development of drug-resistant cancer cells. The recent discovery of microRNAs (miRNAs) has drawn attention from cancer researchers due to their role in regulating gene expression. Circulating exosomes may carry extracellular miRNAs that serve as prognostic indicators for cancer. There is an urgent need for new biomarkers to improve prostate cancer diagnosis. Recent studies suggest that serum exosomal miRNAs could be effective, noninvasive biomarkers for specific conditions. Exosomal miRNA has emerged as a reliable biomarker for diagnosing and treating prostate cancer. It may also serve as a potential therapy for the disease. Based on clinical and preclinical research, this review explores current knowledge about exosomal miRNAs in prostate cancer diagnosis and treatment, as well as their potential for disease monitoring. Furthermore, this analysis emphasizes the complex role of exosomal microRNAs in prostate cancer development and treatment resistance, including their impact on immune evasion, stromal cell activation, niche formation, and metabolic alterations.
Indexed as
Identifiers
41284143What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.